SYRE
Spyre Therapeutics Inc.
87.10$
-1.2%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +64.9% | +42.6% | -10.6% | -3.4% | +44.5% | -6.4% | -5.4% | -6.4% | +54.1% | -1.8% | +53.5% | |
| – | +65.8% | +42.7% | -10.6% | -3.4% | +44.5% | -6.4% | -5.4% | -6.4% | +54.1% | -1.8% | +53.5% | |
| – | +108.5% | +20.5% | -80.2% | +58.6% | +24.9% | -45.8% | +68.4% | -20.5% | +32.1% | +13.4% | +66.7% | |
| – | +66.6% | +42.8% | -12.1% | -2.8% | +45.6% | -6.3% | -6.8% | -7.7% | +55.6% | -2.0% | +54.5% | |
| – | – | – | – | – | – | – | – | +2.9% | – | – | – | |
| – | -65.1% | +112.4% | -81.6% | +51.9% | -3.2% | -3.9% | -4.7% | -40.4% | +26.3% | +48.9% | -22.8% | |
| – | -28.7% | +33.9% | -48.3% | +160.1% | -6.0% | +30.7% | +17.5% | -44.3% | +26.8% | +45.1% | -25.7% | |
| – | -46.6% | +246.7% | +4.0% | +59.9% | -87.1% | +453.9% | +0.6% | +100.9% | +19.4% | -36.1% | +0.5% | |
| – | – | -17.3% | +145.9% | -12.6% | +58.2% | -6.8% | -5.6% | -0.1% | +57.2% | -6.2% | +64.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +405.5% | +68.2% | +24.1% | +12.3% | -7.6% | +28.2% | +0.7% | -0.5% | +24.3% | +4.6% | +7.9% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.